Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06435689
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-30
First Post:
2024-05-26
Brief Title:
Study and Modulation of Immune Responses in Primary and Metastatic Colon Cancers
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
Etude et Modulation de la réponse Immunitaire Dans Les Cancers COlorectaux Primaires et METastatiques
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
I-COMET
Brief Summary:
Colorectal cancer CRC is the 3rd most common cancer in France Treatment of CRC relies primarily on surgical removal of the primary tumor and chemotherapy is the current standard of care for synchronous metastatic disease Overall survival remains strongly correlated with the tumor stage at the time of surgery from 90 at five years for localized disease stages 1 and 2 to around 20 for metastatic forms of the disease stage 4 Recent research in cancer highlights the role of the immune system in the development evolution and fate of tumors Understanding the nature of interactions between different immune cells infiltrating the tumor is important for the development of innovative therapies Recently the consensus molecular classification of CRC confirmed the importance of the immune response in CRC by showing that a high immune response is a good prognostic indicator for patients with this pathology However immunotherapies are effective for only a minority of patients with metastatic CRC Indeed anti Programmed cell Death 1 anti-PD-1 -PD-L1 immune checkpoint blocking antibodies have only shown effectiveness in patients with microsatellite instability MSI which only represents 5 of metastatic CRCs
Thus the aim of this study is to better understand the role of the immune system on the development of CRC and its possible modulation to treat or prevent metastatic recurrences
Thus the aim of this study is to better understand the role of the immune system on the development of CRC and its possible modulation to treat or prevent metastatic recurrences
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None